Ринокленил

Quick links to important sections

Ринокленил

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ринокленил

What is Ринокленил? (Rinoclenil)

Property Description
Active ingredient Beclometasone dipropionate
Form Aqueous suspension nasal spray
Pharmacological class Synthetic Glucocorticoid (Corticosteroid)
General purpose Management of nasal inflammation and swelling
Origin Synthetic

What Type of Medicine is Ринокленил?

Ринокленил is a single-component pharmaceutical preparation classified fundamentally as a corticosteroid, belonging specifically to the high-potency group of synthetic glucocorticoids. This medicine is designed for intranasal (topical mucosal) administration, a delivery method clinically recognized for focusing the drug’s action directly where it is needed, such as in the control of persistent nasal discomfort. The drug's classification in the WHO Anatomical Therapeutic Chemical (ATC) system places the active substance, Beclometasone, under topical nasal agents, which emphasizes its local site of action.

Composition: What is the Active Ingredient in Ринокленил?

The sole active ingredient in this medicine is Beclometasone dipropionate (INN). Beclometasone dipropionate is a substance used to achieve potent local anti-inflammatory effects with minimal systemic absorption. This characteristic is a key differentiating factor, enabling focused action. It is formulated as an aqueous suspension nasal spray, utilizing a purified water base and stabilizing agents as the base/vehicle for effective dispersion. Beclometasone dipropionate functions as a prodrug; upon contact with the nasal mucosa, it is rapidly converted into its principal, highly active metabolite, Beclometasone 17-monopropionate, which mediates the therapeutic effects.

The General Purpose of This Glucocorticoid Preparation

The general purpose of Ринокленил is to exert a powerful anti-inflammatory and immunosuppressive effect directly on the nasal lining. This action is rooted in the substance's role as a Glucocorticoid Receptor Agonist, which works by attenuating inflammatory responses at the cellular level. By modulating the biological cascade that causes irritation and swelling, the preparation generally helps to manage chronic mucosal symptoms, such as those associated with severe or prolonged irritation, through the focused control of underlying inflammation and tissue swelling in the nasal passages.

Regulatory References

  1. European Medicines Agency (EMA) - Trydonis EPAR

What side effects are possible with Ринокленил?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse effects and safety characteristics for this medicine, based strictly on authoritative government regulatory documents.

Documented Adverse Reactions

The majority of reported adverse reactions are local, related to the intranasal route of administration. These effects are classified by regulatory frequency standards.

Frequency Classification Examples of Adverse Reactions
Common (1/100 to <1/10) Epistaxis (nosebleeds), Nasal and throat dryness, Nasal irritation, Hypersensitivity reactions (e.g., rash)
Very Rare (<1/10,000) Nasal septum perforation, Cataract, Glaucoma, Anaphylactic reactions, Bronchospasm

Serious Adverse Reactions and Systemic Risks

Certain rare but serious adverse reactions are documented, primarily linked to the drug's corticosteroid class.

  • Ocular Complications: The label lists Glaucoma and Cataract as potential rare effects, primarily associated with prolonged use.
  • Systemic Effects: The potential for Adrenal suppression and features of Cushing's syndrome is documented, particularly following high doses prescribed for prolonged periods.
  • Serious Allergic Reactions: Severe hypersensitivity reactions, including Anaphylaxis and Bronchospasm, are classified as very rare.

Population and Duration-Related Safety Notes

The regulatory safety profile includes specific notes for certain groups and contexts:

  • Pediatrics: The potential for growth retardation is documented in children and adolescents receiving nasal corticosteroids, requiring height monitoring during prolonged treatment.
  • Long-Term Exposure: The most serious systemic risks are cited as being more likely with high doses prescribed for prolonged periods.
  • Restrictions: Use is cautioned or contraindicated in the presence of untreated localized infections of the nasal lining or in individuals with recent nasal trauma or surgery.
  • Excipient Warning: The excipient Benzalkonium Chloride is documented as a substance that may cause nasal irritation or swelling and may induce bronchospasm.

Overdose and Emergency Response

Overdose Scope

Documented overdose presentations:

  • The only harmful effect documented following acute, short-term over-inhalation is transient suppression of Hypothalamic-Pituitary-Adrenal (HPA) function.
  • Chronic excessive use may lead to symptoms of hypercorticism, which can include menstrual irregularities, acneiform lesions, and cushingoid features.

Physiological systems affected (as stated in label):

  • Endocrine System (HPA axis function).

Dose-related or exposure-related factors (if applicable):

  • Acute overdosage is considered unlikely due to the low total amount of active ingredient in the nasal spray formulation.

Population-specific overdose notes (if applicable):

  • Individuals with a history of recent systemic steroid therapy are noted as potentially more susceptible to hypercorticism with excessive use.

Emergency-response statements (as written in official documents):

  • No special emergency action need be taken for cases involving acute, short-term overdosage.
  • Management is supportive and requires appropriate monitoring.

When immediate medical help is required (label-derived phrasing only):

  • Urgent medical guidance is required if clinical signs of hypercorticism are evident, as this necessitates slow discontinuance consistent with established procedures for oral steroid therapy.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents):

  • Acute short-term overdose results in transient HPA function suppression.

Overdose-context constraints (as defined in official documents):

  • No specific treatment or antidote is known.
  • Consultation with a national poisons centre is recommended for further clinical management guidance.

Resulting Overdose Structure

Official overdose statements:

  • No special emergency action need be taken for an acute overdose.
  • The only harmful effect from short-term exposure is transient suppression of HPA function.
  • There is no specific treatment known; management is strictly supportive.

Connection to the overall overdose profile: Regulatory documents define the overdose profile of Rinoclenil by its low acute toxicity, stating that no special emergency action is required for short-term exposure due to the transient nature of the primary effect. The imperative to seek medical guidance is tied instead to managing chronic excessive use that leads to systemic glucocorticoid effects and obtaining professional advice for supportive care.

Therapeutic Uses of Ринокленил

What Ринокленил Treats: Main Uses and Benefits

The medication is used in areas where short-term symptom management is appropriate, applied across domains where additional symptomatic support is needed for conditions where functional stability becomes affected. The medication is commonly used to help with symptom clusters related to inflammatory or irritative states.

The medication is relevant in conditions characterized by periods of heightened symptoms, specifically allergic rhinitis (including hay fever and year-round allergies), vasomotor rhinitis, and as supportive treatment for nasal polyposis. It helps address symptom clusters that may become intense or disruptive, including persistent nasal congestion, rhinorrhea (runny nose), nasal itching, and frequent sneezing.

This support is relevant in contexts where additional management of discomfort is required, such as after surgical removal of polyps (polypectomy). This ongoing use assists with maintaining functional stability and supports general well-being during symptomatic phases.


Quick Fact: Helps Address Symptoms of Persistent Nasal Obstruction

Regulatory References

  1. NIH MedlinePlus overview of Beclometasone

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ринокленил

This section outlines the officially documented population eligibility and restrictions for using this medicine, strictly based on regulatory prescribing information.


Populations for Whom Use is Restricted or Contraindicated

Classification Population or Condition
Absolute Contraindication Patients with a known hypersensitivity or allergy to beclometasone dipropionate or any of the product’s excipients.
Restricted Use Patients with untreated localized infection involving the nasal mucosa (e.g., Candida albicans).
Avoid Use Individuals with recent nasal surgery, trauma, or septal ulcers until complete healing has occurred.

Age and Comorbidity Restrictions

  • Age Eligibility: The medicine is typically approved for adults and adolescents (12 years and older). Use is also approved for some formulations in children aged 4 to 11 years, but is generally not established or not recommended for children under 4 years of age.
  • Pregnancy and Lactation: Use during pregnancy is restricted and permitted only when the potential benefit is judged to outweigh the potential risk. Caution is advised during lactation as excretion into human milk is unknown.
  • Comorbidity Caution: Use requires monitoring or caution in patients with a history of increased intraocular pressure, glaucoma, or cataracts, and in those with systemic infections such as tuberculosis or ocular herpes simplex.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section describes interactions for beclomethasone dipropionate (Ринокленил) that are officially documented in government regulatory labeling. The primary focus is on agents that can alter the drug's systemic exposure or increase the risk of systemic corticosteroid side effects.


Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance/Class Regulatory Status Constraint Summary
Inhibition of Clearance Strong CYP3A Inhibitors (e.g., ritonavir, cobicistat) Use with Caution/Avoidance May increase systemic exposure to the active metabolite, requiring close monitoring.
Additive Effects Other Systemic or Inhaled Corticosteroids Caution Warranted Increases the risk of HPA axis suppression and other glucocorticoid-related effects.

Population and General Notes

Official labeling indicates that co-administration with strong CYP3A inhibitors should generally be avoided unless the therapeutic benefit is deemed to outweigh the increased potential for systemic corticosteroid adverse effects. No specific timing or dose separation requirements are documented for co-administered medicines.

Due to the drug's reliance on hepatic metabolism for clearance, caution is warranted in patients with hepatic impairment, as this condition may lead to decreased clearance and a potential increase in systemic drug levels. No clinically significant interactions with food, alcohol, or herbal products are explicitly documented in regulatory materials.

Mechanism of Action

The mechanism of action for Ринокленил is derived from its sole active ingredient, Beclometasone dipropionate, a prodrug that is locally converted into its highly active metabolite, Beclometasone 17-monopropionate. The mechanism operates by localized immunosuppression and anti-inflammation, driven by the agonism of the intracellular Glucocorticoid Receptor (GR). This genomic action precisely modulates key transcription factors and signaling cascades within the cells of the nasal lining.


Regulating Inflammation at the Genetic Level

The mechanism is initiated by a genomic process that includes transrepression and transactivation. Transrepression blocks the activity of pro-inflammatory factors, such as NF-kappaB, limiting the cell's capacity to generate pro-inflammatory signals. Simultaneously, transactivation increases the production of anti-inflammatory proteins, like Annexin A1. This regulatory control over gene expression restricts the production of inflammatory messengers.


Reducing Key Inflammatory Mediators

The genomic modulation leads to a reduction of inflammatory mediators. The resulting Annexin A1 synthesis indirectly inhibits the enzyme Phospholipase A2 (PLA2), thereby disrupting the initial step of the Arachidonic Acid Pathway. This blockade limits the formation of inflammatory chemicals, including Prostaglandins and Leukotrienes. The reduction in these mediators results in the physiological consequence of decreased fluid extravasation and tissue bulk.


️ Mechanism Constraints and Time Profile

The anti-inflammatory effects are not immediate because they rely on the time required for these genomic changes (gene transcription and new protein synthesis) to occur and achieve full pathway modulation. This delayed onset is a key constraint of the glucocorticoid mechanism. Furthermore, the mechanism involves inflammation modulation and does not engage in alpha-adrenergic agonism, meaning it does not produce the rapid vasoconstriction or immediate tissue shrinkage associated with sympathomimetic agents.

Dosage and Administration Information

How to Use Ринокленил

Ринокленил (Beclometasone dipropionate) is administered solely via the intranasal route as an aqueous suspension, a method which allows for the topical application of the drug directly to the nasal lining. Consistent daily administration is an essential procedural condition for this medicine.


Administration Regimens and Frequency

The medicine follows a standardized dosing structure. The typical adult starting regimen is established as two sprays into each nostril, administered either once daily (QD) or twice daily (BID). This results in a total daily dose that commonly ranges between 320 mcg/day and 400 mcg/day of Beclometasone dipropionate, depending on the specific product strength and regional label. Once initial symptomatic control is achieved, the protocol involves a dose titration to the minimum effective maintenance level, which often involves reducing the frequency or number of sprays (e.g., one spray per nostril, once or twice daily).

Preparation and Procedural Use

Specific steps are required to ensure the device delivers the correct dosage. The bottle of the aqueous suspension must be shaken vigorously before each use. Before first administration, or following a period of non-use (typically seven days), the pump mechanism must be primed with a set number of actuations into the air. If a dose is missed, it should be administered as soon as possible, but doubling the dose to compensate for a missed dose is explicitly prohibited. The continuation of the therapy should be reassessed if no significant symptomatic improvement is observed after three weeks of regular use.

Population-Specific Use

Age-based limitations apply to administration. The product is generally not recommended for children under six years of age. For children between six and twelve years, the maximum total daily dose is lower than the adult limit, with regimens often beginning at one spray in each nostril once or twice daily.

Recent Clinical Evidence

Research evidence / Overview of studies for Ринокленил

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Ринокленил (Beclometasone Dipropionate) was studied for conditions characterized by fluctuating or episodic manifestations, such as the symptoms of allergic rhinitis. Research has primarily examined this use through Randomized Controlled Trials (RCTs), which are the primary design used for clinical research and compare the medicine against a placebo or inactive substance. Studies was evaluated in populations of Adults, Adolescents, and Children (down to 4 years of age). Outcomes related to physical discomfort was monitored using measurement tools like Total Nasal Symptom Scores (TNSS), and patient-reported experiences were tracked using Quality of Life (RQLQ) scores. Studies reported measurements of shifts in these scores, tracking symptom assessments over periods that included two weeks.


Evidence for Use in Nasal Polyposis

Research also explored the role of Ринокленил in the management of nasal polyposis. The evidence for this indication research examined specific RCTs and integrated data, focusing on Adults who had undergone the surgical removal of polyps. Researchers examined outcomes related to systemic or functional imbalance, such as the size and number of polyps, using endoscopic scoring. Studies recorded how symptoms were tracked following the surgical baseline, and research describes data recorded for measurements of recurrence patterns.


Long-Term Evidence and Study Duration

The available evidence includes both short-term trials and longer-duration studies to assess symptom patterns. Studies observed responses over defined time intervals extending from six to twelve weeks, with some research monitored outcomes for up to one year (52 weeks). This evidence was studied for tracking symptom patterns over extended periods. However, long-term effects are not fully established, and research is ongoing for certain outcomes.


Evidence in Special Populations and Research Gaps

The research base was evaluated in children, adolescents, and adults. For children, specific monitoring regarding potential effects on growth rate was observed in some studies to address specific monitoring questions. Data for certain groups remain insufficient. While studies describe group patterns, the results apply only to the populations studied, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Beclomethasone Nasal Spray: MedlinePlus Drug Information
  2. Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Ринокленил (FAQ)


Q: Can I use Ринокленил all year round?

Studies have examined the use of the active ingredient in Ринокленил over periods extending up to one year to monitor symptom patterns. Official guidelines emphasize that once the initial symptoms are controlled, the use should be adjusted to the minimum effective maintenance level. Consistent daily use supports the medicine's intended anti-inflammatory effect.


Q: Can children use Ринокленил for non-allergic conditions?

Regulatory indications include the management of symptoms associated with specific conditions such as allergic rhinitis and vasomotor rhinitis, which is non-allergic. It is also approved for the prevention of nasal polyps. However, official materials explicitly state that it is not recommended for treating symptoms caused by the common cold.


Q: Do studies support the use of Ринокленил for chronic sinus issues?

Official product information describes the medicine as indicated for managing symptoms associated with allergic rhinitis and for preventing the recurrence of nasal polyps. Nasal polyps are considered a chronic sinus condition, and studies have examined the medicine for this use. Regulatory documents do not consistently define the use of the medicine for non-polyp chronic sinus issues in general.


Q: Is Ринокленил a preventative medicine or a treatment for acute symptoms?

According to official information, Ринокленил functions best as a control for chronic symptoms. Its anti-inflammatory effect is not immediate, and it is described as working best when administered consistently on a regular schedule. It is generally not indicated to relieve sudden or acute symptoms, such as immediate congestion relief.


Q: Is Ринокленил safe for individuals with liver or kidney conditions?

Official product labeling advises caution for patients with existing hepatic impairment (liver conditions), as this may slow the body’s clearance of the medicine. Some regulatory information also notes caution regarding kidney (renal) problems.


Q: What happens if Ринокленил is used for longer than the recommended period?

Using the medicine at high doses for prolonged periods may increase the potential for systemic effects, meaning effects beyond the nose. Official safety information details the rare possibility of issues such as adrenal suppression, features related to Cushing’s syndrome, and ocular complications like glaucoma or cataracts.


Q: Can Ринокленил be used to treat a common cold?

Regulatory documents explicitly state that this medicine is not to be used for treating symptoms caused by the common cold. Its approved indications relate to the management of chronic conditions such as allergic rhinitis and nasal polyps.


Q: Does Ринокленил cause drowsiness?

Drowsiness, also known as somnolence, is not listed as a common side effect in official adverse reaction profiles. Because the medicine is primarily locally acting, systemic effects that could lead to symptoms like confusion or dizziness are considered rare.


Q: Is it normal to feel a change in taste or smell after starting Ринокленил?

Official post-marketing and safety reports have documented the possibility of experiencing an unpleasant taste or smell (known as dysgeusia or dysosmia). This effect is recognized in official safety summaries as a possible reaction to the nasal spray.


Q: Are there known interactions between Ринокленил and common pain relievers?

Regulatory interaction summaries primarily detail precautions for co-administering the medicine with strong CYP3A inhibitors or other corticosteroids. However, no specific or significant interactions with common pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs), are typically documented in the official regulatory summaries.


Q: Can Ринокленил affect birth control pills?

Based on official regulatory interaction summaries, there is no known or documented interaction between the active ingredient in Ринокленил and oral contraceptive pills (birth control pills).


Q: Is it possible to become dependent on using Ринокленил?

Ринокленил is not classified as a controlled substance and is not associated with the behavioral or physiological dependence often linked to traditional decongestant sprays. Official safety warnings describe the potential for systemic effects, such as adrenal suppression, if high doses are used for very long periods.


Q: What is the typical duration of effect for a single use of Ринокленил?

Although the full anti-inflammatory benefits rely on consistent use over several days or weeks, the recommended dosing schedule is often twice daily. This suggests that one administration of the medicine is generally intended to cover a period of approximately 12 hours.


Q: Are there specific instructions regarding stopping the use of Ринокленил?

Official patient information notes that stopping the use of this medicine should be discussed with a healthcare professional. Suddenly discontinuing the use of the medicine may increase the chance of the original symptoms returning or may cause other effects.


Q: Is Ринокленил classified as a controlled substance in any official capacity?

The active ingredient in Ринокленил, Beclometasone dipropionate, is not classified as a controlled substance by international narcotics control bodies or major regulatory agencies.


Q: Do official materials specify restrictions on driving while using Ринокленил?

Because the medicine acts locally on the nasal lining, it is not generally expected to affect the ability to drive or operate machinery. If rare systemic side effects that cause dizziness or impaired concentration occur, official guidance notes that a consultation with a doctor may be necessary.


Q: Is a metallic taste a known possible effect of Ринокленил?

An unpleasant taste in the mouth is a documented side effect reported in post-marketing surveillance for Beclometasone nasal spray. This effect is not universally experienced but is recognized in official safety summaries.


Q: Does Ринокленил help with throat symptoms as well as nasal ones?

The medicine's primary indication, as described in regulatory documents, is the management of symptoms originating from inflammation within the nasal lining. While official information lists throat dryness as a common side effect, the medicine is not generally indicated as a primary treatment for general throat symptoms.


Q: What should be done if a large amount of Ринокленил is accidentally swallowed?

Official product information notes that the nasal spray should not be swallowed during administration. If a large amount of the medicine is accidentally swallowed, official guidance specifies that immediate consultation with a doctor or emergency medical attention is required.


Q: Is it possible for Ринокленил to cause a headache?

Yes, headache is reported as a potential side effect in the official adverse reaction profile for this medicine. It is typically classified as a common or less common effect in regulatory summaries.


Q: Can people with high blood pressure safely use Ринокленил?

The official safety warnings for the nasal formulation do not typically list high blood pressure (hypertension) as a primary contraindication. Warnings are generally focused on rare systemic risks like adrenal suppression and ocular complications.

How should Ринокленил be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal of the nasal spray must strictly follow regulatory guidance to ensure product integrity and safety.


Storage Conditions

  • Store the product at room temperature, ensuring the temperature does not exceed 30 C (86 F).
  • The spray must be protected from excess heat, moisture, and direct light; it is mandatory to not freeze or refrigerate the container.
  • Keep the medicine in its original container, tightly closed, and stored out of the sight and reach of children.

Stability and Discarding

  • Discard the bottle three months after first opening or once the total labeled number of metered sprays has been administered.

Disposal

  • Dispose of unused or expired product in accordance with local regulatory requirements.
  • Do not pour the medicine down drains and do not puncture or place the container into a fire.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ринокленил found in:

A-Z Index: